Switzerland-based pharmaceutical company,
) recently announced phase III data on its pipeline candidate,
RLX030 (serelaxin), from the six month, RELAX-AHF study.
The study showed that treatment with RLX030 reduced the rate of
mortality in patients suffering from acute heart failure (AHF),
which has a higher death rate compared to other cardiovascular
The phase III RELAX-AHF study had two primary objectives which
used different scales for measuring the reduction in dyspnea. The
study managed to achieve one of the primary objectives. The study
also revealed that RLX030 was well tolerated in patients.
The randomized, double-blind study, RELAX-AHF was conducted in
1,161 patients in 11 countries. The study evaluated the safety and
efficacy of the candidate, RLX030, in the AHF indication versus
RLX030 along with loop diuretics and other medicines was
administered to patients for up to 48 hours following
Novartis intends to discuss the results from the study with
regulatory authorities around the globe. Data from the study will
also be presented at the American Heart Association congress in
Already approved heart failure treatments include
) Toprol XL and
Merck & Co.
We remind investors that in August 2012, Novartis had reported
positive phase II data on its pipeline candidate, LCZ696, from the
PARAMOUNT study for the treatment of chronic heart failure.
The study showed significant reduction in a key indicator of
morbidity and mortality in patients suffering from chronic heart
failure with preserved ejection fraction (HF-PEF).
Currently, we have a Neutral recommendation on Novartis.
Novartis carries a Zacks #3 Rank (Hold rating) in the short
ASTRAZENECA PLC (AZN): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
To read this article on Zacks.com click here.